Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants
British Journal of Clinical Pharmacology · 2025-09 · 91 (9) · 2736-2744
DOI: 10.1002/bcp.70078 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 21.05.2025. Verfasst von Dongxu Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Beijing, China. Hauptthemen laut MEDLINE: Hemorrhage, Atrial Fibrillation, Thromboembolism, Factor Xa Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Aims
Gene polymorphisms play a critical role in the variability of plasma concentrations of direct‐acting oral anticoagulants (DOACs). In this study, we aimed to investigate the effects of genetic variants on the clinical outcomes of Chinese patients treated with DOACs.
Methods
The retrospective study recruited 720 patients with nonvalvular atrial fibrillation who were receiving dabigatran, rivaroxaban or edoxaban. Cox regression models were employed to compare the clinical outcomes between carriers and noncarriers of the key single nucleotide polymorphisms.
Results
Results revealed that the CES1 rs2244613 C allele significantly reduced bleeding events in patients treated with dabigatran (adjusted hazard ratio 0.33, 95% confidence interval 0.13–0.85, P = .021). The carriage of ABCB1 rs1045642 T allele was associated with a lower risk of thromboembolism in rivaroxaban users (adjusted hazard ratio 0.19, 95% confidence interval 0.07–0.57, P = .003). Additionally, a trend toward statistical significance ( P = .052) was observed between the SLCO1B1 rs4149056 C allele and bleeding risk among the edoxaban users.
Conclusions
Our study showed that the CES1 rs2244613 and ABCB1 rs1045642 alleles were associated with outcome events in Chinese patients taking dabigatran and rivaroxaban, respectively. The findings could help predict clinical outcomes and develop personalized anticoagulation treatment strategies for Chinese patients taking DOACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Department, Beijing Hospital, National Center of Gerontology, Beijing, China.
- Arrhythmia Center, Fuwai Hospital, Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, Beijing, China.
- Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, China.
- Department of Clinical Laboratory, Beijing Hospital, National Center of Gerontology, Beijing, China.
ORCID-Profile: Dongxu Wang
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Wang, D., An, Y., Zhou, X., Chai, H., Huo, J., Li, C., Du, M., Dai, D., Li, C., & Chen, H. (2025). Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants. British Journal of Clinical Pharmacology, 91(9), 2736-2744. https://doi.org/10.1002/bcp.70078
Vancouver
Wang D, An Y, Zhou X, Chai H, Huo J, Li C, et al. Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants. British Journal of Clinical Pharmacology. 2025;91(9):2736-2744. doi:10.1002/bcp.70078
BibTeX
@article{Wang2025,
author = {Wang, Dongxu and An, Yang and Zhou, Xiaoyue and Chai, Huaru and Huo, Jiani and Li, Chunrong and Du, Minghui and Dai, Dapeng and Li, Chuanbao and Chen, Hao},
title = {Relevance of selected pharmacogenetic polymorphisms to bleeding and thromboembolic risks in Chinese patients taking direct‐acting oral anticoagulants},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {9},
pages = {2736--2744},
doi = {10.1002/bcp.70078}
}
EUVIMED